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Abstract
Interleukin (IL)-33, the most recent member of the IL family of cytokines, signals through the ST2 receptor. IL-33/ST2 signaling
mediates antigen challenge-induced mechanical hyperalgesia in the joints and cutaneous tissues of immunized mice. The
present study asked whether IL-33/ST2 signaling is relevant to overt pain-like behaviors in mice. Acetic acid and phenyl-p-
benzoquinone induced significant writhing responses in wild-type (WT) mice; this overt nociceptive behavior was reduced in
ST2-deficient mice. In an antigen-challenge model, ST2-deficient immunized mice had reduced induced flinch and licking overt
pain-like behaviors. In the formalin test, ST2-deficient mice also presented reduced flinch and licking responses, compared
with WT mice. Naive WT and ST2-deficient mice presented similar responses in the rota-rod, hot plate, and electronic von Frey
tests, indicating no impairment of motor function or alteration in basal nociceptive responses. The results demonstrate that IL-
33/ST2 signaling is important in the development of overt pain-like behaviors.
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Introduction
Overt nociception/overt pain-like behavior models are
widely used to assess the activity of novel candidate
analgesic drugs and their mechanisms of action. These
tests involve the injection of stimuli with irritating
characteristics, which rapidly promotes behaviors such
as abdominal writhing, flinching, or licking of the injected
paw (1-6). The stimuli are generally chemical [e.g.,
phenyl-p-benzoquinone (PBQ), acetic acid, formalin]
(1-3), but may also be biological (e.g., zymosan) (5) or
even an antigen (4).
Abdominal writhing induced by acetic acid or PBQ is
dependent on the release of inflammatory mediators, such
as cytokines and prostanoids (2,5). In the PBQ model,
writhing depends on the cytokines interleukin (IL)-18,
interferon gamma (IFN-c), and endothelin-1 (ET-1) (2).
The mechanism for mediating the acetic acid-induced
writhing response (2) depends on activation of peritoneal
macrophages and mast cells that then release cytokines,
such as tumor necrosis factor-a (TNF-a), IL-1b, and IL-8,
as well as eicosanoids and sympathomimetic amines (5).
Nevertheless, despite differences in the peripheral
mediators involved in PBQ- and acetic acid-induced
writhing responses, both depend on spinal activation of
mitogen-activated protein kinases, phosphatidylinositol
3-kinase and microglia (1).
In the formalin test, the subcutaneous injection of
formalin into the mouse hind-paw induces a nociceptive
response that consists of two phases. Phase 1 (0-5 min
after formalin injection) is the neurogenic phase and is
generally attributed to a direct effect of the stimulus on
nociceptors, whereas phase 2 (10-30 min after formalin
injection) involves the subsequent development of inflam-
mation, which is mediated by cytokines, such as TNF-a,
IL-1b, IL-6, and IL-8, and prostaglandins (PGs) (6-9).
Overt pain-like behavior can also be induced by antigen
challenge in immunized animals (4). For instance,
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intraplantar injection of ovalbumin (OVA) induces sig-
nificantly more paw licking in immunized mice than in non-
immunized mice, by an ET-1-dependent mechanism (4).
IL-33 is the most recent addition to the IL-1 cytokine
family that includes IL-1b and IL-18. IL-33 exerts its
biological activity by interacting with a heteromeric
receptor composed of ST2, the IL-33 specific subunit of
the receptor, and the IL-1 receptor accessory protein,
which is shared with IL-18 (10,11). IL-33 is a pleiotropic
cytokine implicated in various inflammatory conditions
and diseases (11). IL-33 plays a role in Th1, Th2, and
Th17 adaptive responses, innate inflammation, and as an
endogenous danger signal (11).
IL-33/ST2 signaling is involved in pain (12). IL-33
mediates methylated bovine serum albumin (mBSA)-
induced cutaneous and articular mechanical hyperalgesia
in immunized mice via activation of the TNF-a R IL-1b R
IFN-cRET-1RPGE2 signaling cascade (12). Furthermore,
IL-33/ST2 signaling contributes to carrageenan-induced
innate inflammatory pain, triggering the production of
TNF-a, CXCL1, IL-1b, ET-1, and PGE2 (13). These data
suggest that the role of IL-33 in pain is wider than just its
involvement in innate and Th1/Th17-dependent mechanical
hyperalgesia (12,13) because the molecules produced in
response to IL-33 also mediate nociceptive responses in
other pain models, as well as promoting overt pain
behaviors (2,4,5,7). Thus, in this study, we used ST2-
deficient mice to investigate the role of IL-33/ST2 signaling
in abdominal writhing induced by acetic acid and PBQ, and
in formalin- and OVA challenge-induced paw flinch and
licking responses in naive and immunized animals,
respectively.
Material and Methods
Reagents
Acetic acid and formalin were obtained from
Mallinckrodt Baker S.A. (Mexico), PBQ and OVA were
from Sigma-Aldrich (USA), and DMSO was from Merck
(Germany). The doses of these stimuli were chosen
based on pilot studies and previous data from our
laboratory (1,2,6).
Animals
All experiments were performed on sex-matched
BALB/c wild-type (ST2+/+) and BALB/c background
ST2-deficient (ST2-/-) mice (14), weighing 20-25 g. The
experiments were conducted between 9:00 am and 5:00
pm. The mice were bred at the Faculdade de Medicina de
Ribeira˜o Preto, Universidade de Sa˜o Paulo, Brazil. Animal
care and handling procedures were in accordance with
the International Association for the Study of Pain
guidelines and with the approval of the Ethics
Committee of the Faculdade de Medicina de Ribeira˜o
Preto, Universidade de Sa˜o Paulo, Brazil. All experiments
were double-blinded.
Writhing response tests
The PBQ- and acetic acid-induced writhing model
experiments were performed as described previously,
using the same doses (1,2). PBQ (630 mg diluted in
10 mL 2% DMSO in saline), acetic acid [0.6% (v/v) diluted
in saline], or vehicle was injected (10 mL/kg) into the
peritoneal cavity of each mouse. Next, each mouse was
placed in a large glass cylinder, and the intensity of
nociceptive behavior was quantified by counting the total
number of writhing responses (contraction of the abdominal
muscles together with stretching of hind limbs or rotation of
the trunk) occurring between 0 and 20 min after stimulus
injection. The intensity of the writhing response was
expressed as the cumulative number of movements
occurring in 2-min bins over 20 min.
Formalin test
The number of paw flinches and time spent licking the
paw were counted between 0 and 30 min after intraplantar
injection of formalin [2.5% (v/v) diluted in 25 mL saline] or
vehicle as described previously (6). The period was divided
into 5-min bins, which clearly demonstrated the presence
of the first (0-5 min) and second (10-30 min) phases that
are characteristic of the model (6-9).
Measurement of motor coordination/function
Mouse motor coordination/function was evaluated
using the rota-rod test. The apparatus consisted of a
2.5-cm diameter bar that was subdivided into 6 compart-
ments by 25-cm diameter disks (model 7600; Ugo Basile,
Italy). Mice were placed on the bar while it was rotating at
constant speeds of 10 or 15 rotations per min (rpm), and
the duration that they were able to remain on it was
determined. The cutoff time used was 180 s.
Hot plate test
Mice were placed in a 10-cm diameter glass cylinder
on a hot plate (Hot Plate HP-2002, Insight Equipamentos,
Brazil) maintained at 556C. The reaction time was scored
when the animal jumped, flinched or licked its paws. A
maximum latency (cutoff) was set at 30 s to avoid tissue
damage (6).
OVA immunization procedure and challenge
Mice were immunized with a single subcutaneous
dose of 50 mg OVA plus 5 mg Al(OH)3, diluted in 200 mL
sterile saline. After 14 days, mice were challenged with
1 mg/paw OVA or vehicle (saline). The number of paw
flinches and time spent licking the paw was determined
over 30 min (4). The dose of the antigen challenge was
determined by preliminary studies in our laboratory.
Statistical analysis
Results are reported as means±SE of 7 mice per
group per experiment, and represent two separate
experiments. Statistical differences between groups
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were determined by the two-tailed Student t-test for
unpaired samples (Figures 1 and 3) or one-way ANOVA
followed by the Bonferroni t-test (Figure 2). All statistical
analyses were performed using the GraphPad Prism 5
software (USA). The significance level was set at
P,0.05.
Results
Role of IL-33/ST2 in PBQ- and acetic acid-induced
writhing responses
The role of IL-33/ST2 was evaluated in PBQ- and
acetic acid-induced overt pain-like behavior. ST2-/- mice
showed reduced PBQ-induced writhing responses com-
pared with ST2+/+ mice (Figure 1A). The differences
were significant at each interval between 10 and 20 min.
Acetic acid-induced writhing responses were also
diminished in ST2-/- mice, compared with ST2+/+ mice
(Figure 1B), and the differences were significant between
4 and 20 min. The vehicles, saline and 2% DMSO in
saline, did not induce writhing responses in any of the
mice (data not shown).
Role of IL-33/ST2 in OVA-induced paw flinching and
licking
ST2+/+ and ST2-/- mice challenged with 1 mg/paw
OVA 14 days after immunization with the antigen
displayed paw flinches and licking behavior. Both the
paw flinches (Figure 2A) and time spent licking the paw
Figure 1. Role of IL-33/ST2 receptor in phenyl-p-benzoquinone
(PBQ)- and acetic acid-induced writhing responses. ST2+/+ and
ST2-/- mice received an intraperitoneal injection (10 mL/kg) of A,
PBQ (630 mg diluted in 10 mL 2% DMSO in saline) or B, 0.6%
acetic acid diluted in saline. The cumulative number of writhing
responses was evaluated between 0 and 20 min and reported at
2-min intervals. n=7 per group per experiment, representative of
two separate experiments. *P,0.05, compared to the ST2+/+
group (Student t-test).
Figure 2. Role of IL-33/ST2 receptor in ovalbumin (OVA)
challenge-induced overt pain-like behavior in immunized mice.
ST2+/+ and ST2-/- mice were immunized with a single dose of
50 mg OVA plus 5 mg Al(OH)3 diluted in saline. After 14 days,
mice were challenged with 1 mg/paw OVA and the number of
flinches (A), and time spent licking the paw (B) were quantified for
30 min. n=7 per group per experiment, representative of two
separate experiments. *P,0.05, immunized ST2+/+ mice
receiving OVA compared to sham-immunized ST2+/+ mice
receiving OVA and immunized ST2+/+ mice receiving saline.
#P,0.05, immunized ST2-/- mice receiving OVA compared to
immunized ST2+/+ mice receiving OVA (one-way ANOVA
followed by the Bonferroni t-test).
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(Figure 2B) induced by OVA challenge were reduced
significantly in ST2-/- mice, compared with ST2+/+ mice.
Vehicle (saline), in immunized mice, and OVA challenge
in the sham-immunized group did not induce significant
flinching or licking behaviors. ST2-/- mice showed the
same responses as ST2+/+ mice in the sham-immunized
group challenged with OVA and the immunized group
challenged with saline (data not shown).
Role of IL-33/ST2 in formalin-induced paw flinching
and licking
The paw flinch responses of ST2-/- mice were reduced
at all time points compared with those of ST2+/+ mice
(Figure 3A), and the time spent licking the injected pawwas
reduced in ST2-/- compared with ST2+/+ mice during the
15-20-min and 25-30-min intervals (Figure 3B). Injection of
vehicle (saline) did not induce flinch or licking responses in
either ST2+/+ or ST2-/- mice (data not shown).
Effect of IL-33/ST2 signaling deficiency on motor
coordination/function and thermal nociceptive
threshold
Rota-rod and hot plate tests were used to evaluate the
role of IL-33/ST2 signaling on motor coordination/function
and thermal nociceptive threshold. No significant differ-
ences (P.0.05) were observed in the time that ST2-/-
mice (179.80±0.20 or 162.40±11.03 s) and ST2+/+
mice (178.70±1.30 or 175.70±4.30 s) remained on the
rota-rod at 10 or 15 rpm, respectively. In the hot plate test,
no significant difference (P.0.05) was observed in the
reaction time of ST2-/- mice (10.45±0.50 s) and ST2+/+
mice (11.45±1.04 s; data not shown).
Discussion
IL-33 is a pleiotropic cytokine involved in adaptive and
innate immune responses (11). The role of IL-33/ST2
signaling in pain was first demonstrated using a Th1/Th17
immunization protocol. Treatment with soluble ST2
reduced antigen challenge-induced mechanical cutaneous
and articular hyperalgesia in mice by preventing the
production of inflammatory molecules, including the cyto-
kines TNF-a, IL-1b and IFN-c, ET-1, and PGE2 (12). It is
interesting to note that IL-18 also mediates hyperalgesia
induced by antigen challenge in immunized mice by
triggering the production of IFN-c, ET-1, and PGE2 (15)
and is an important cytokine in the PBQ-induced writhing
response (2). We reason that IL-33/ST2 signaling could
also contribute to overt pain-like responses, as already
observed in relation to IL-18.
Furthermore, since IL-33 and IL-18 receptors share a
common beta chain, the IL-1 receptor accessory protein
(11), and both receptors mediate hyperalgesia in antigen-
induced inflammation via IFN-c, ET-1 and PGE2, a similar
profile of responses to their activation might be expected.
However, IL-18 mediates the PBQ- but not the acetic acid-
induced writhing response (2), whereas IL-33/ST2mediates
the nociceptive response in both models. IL-33/ST2 triggers
production of TNF-a and IL-1b, which are important
cytokines in the acetic acid-induced writhing response (5).
This mechanism of IL-33, compared with that of IL-18,
explains why IL-33/ST2 mediates both the acetic acid- and
Figure 3. Role of IL-33/ST2 receptor in formalin-induced paw
flinching (A) and time spent licking (B). ST2+/+ and ST2-/- mice
received an intraplantar injection of 25 mL 2.5% formalin diluted in
saline. The overt pain-like behavior was determined as the
number of flinches and time spent licking the paw for 30 min at 5-
min intervals. n=7 per group per experiment, representative of
two separate experiments. *P,0.05, compared to the ST2+/+
group (Student t-test).
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PBQ-induced writhing responses. Thus, it seems likely that
the role of IL-33/ST2 in pain may be broader than that of
IL-18. Furthermore, consistent with a role of IL-33 in
abdominal pain, IL-33 peritoneal fluid and serum levels are
elevated in 75 and 23% of patients with endometriosis,
respectively, primarily in deeply infiltrating endometriosis
presenting painful symptoms, such as dysmenorrhea (16).
In the OVA challenge in immunized mice, the results
indicate a role for IL-33/ST2 in Th2 inflammation-induced
overt pain-like behavior, increasing the possible role of
IL-33/ST2 in nociception beyond Th1/Th17 and innate
responses, as demonstrated previously (12,13). In the
OVA model, mast cell degranulation induces ET-1/ETA
receptor-dependent overt pain-like behavior (4). Likewise,
in the model of Th1/Th17 inflammation in immunized mice
challenged with mBSA, and in innate inflammation
induced by carrageenin, IL-33/ST2 also induces ET-1-
dependent mechanical hyperalgesia (12,13). Thus, it
seems reasonable to expect that IL-33/ST2 could trigger
an ET-1-dependent nociceptive response in Th2 inflam-
mation models, but this phenomenon remains to be
explored further.
In the formalin test, ST2 deficiency resulted in a
decreased response in both phases, mainly in the flinch
response assay, but with significant inhibition seen also in
the second phase of the licking response. In the first
phase of the formalin test, there is participation by mast
cell-derived mediators, such as histamine (8), and,
considering that IL-33 activates the constitutively
expressed ST2 receptors in mast cells (10,11), it is
possible that involvement of IL-33/ST2 in the first phase of
the formalin test might be related to the activation of mast
cell-derived mediators. The reduction in formalin-induced
nociception was more evident in the second phase, with
inhibition of both flinching and licking responses. In that
phase, there is production of cytokines, such as TNF-a
and IL-1b, and inhibition of the activity of those cytokines
reduces nociceptive behavior (7). In antigen- and
carrageenin-induced hyperalgesia IL-33/ST2, signaling
mediates the production of hyperalgesic TNF-a and IL-1b
(12,13). Thus, it seems reasonable to suggest that IL-33/
ST2 could induce overt pain-like behavior in the second
phase of the formalin test by triggering the production of
nociceptive cytokines, such as TNF-a and IL-1b.
During the review process of this manuscript, it was
reported that the intraplantar or intrathecal administration
of IL-33 induces overt pain-like behavior. Moreover,
intraplantar or intrathecal administration of IL-33
increases, and treatment with soluble ST2 (a decoy
receptor for IL-33) reduces, the overt pain-like behavior
induced by formalin (17). Those results are consistent
with the present data and the rationale that IL-33/ST2
signaling itself can trigger overt pain-like behavior.
Furthermore, IL-33 is constitutively expressed in
normal human tissues, and its level is abundant in
endothelial and epithelial cells in vivo, indicating that
IL-33 can be released promptly. IL-33 has a role as a
nuclear factor and is considered to be a ‘‘danger’’ signal,
similar to HMGB1 and IL-1a, functioning as an alarm to
the immune system when endothelial and/or epithelial
cells are subject to damage (18). This concept is in line
with the involvement of IL-33/ST2 in acute nociceptive
events such as the writhing response, in which the
stimulus is injected into the highly vascularized peritoneal
cavity, and the paw flinch and licking responses, with the
possible release of IL-33 by epithelial cells and keratino-
cytes and activation of mast cells, fibroblasts, and
macrophages (11,12,15,16,18,19). Furthermore, ST2 is
expressed by neurons, and IL-33 is expressed by neurons
and astrocytes in the spinal cord of mice in a model of
encephalomyelitis (20), suggesting that IL-33 could be
produced by astrocytes and neurons and act on ST2
receptors expressed by neurons in the spinal cord, which
is consistent with the overt pain-like behavior induced by
the intrathecal injection of IL-33 (17). Nevertheless, the
cellular sources and targets of IL-33 remain to be
determined in pain models to establish whether it has
direct and/or indirect effects on nociceptive neurons.
Notably, differences were not observed between
naive ST2-/- and ST2+/+ mice in the rota-rod, hot plate
(data not shown), or electronic pressure meter tests
(12,13). These data indicate that the motor coordination/
function in ST2-/- mice is preserved, and that there is no
alteration of basal nociceptive responses to thermal or
mechanical stimuli.
In conclusion, the present data indicate that, in
addition to promoting mechanical hyperalgesia (12,13),
IL-33/ST2 signaling is important in overt pain-like behavior
triggered by a variety of phlogistic agents including acetic
acid, PBQ, formalin, and OVA challenge in immunized
mice. These results increase the relevance of IL-33/ST2
signaling in nociception and suggest that the potential of
IL-33 targeting therapies to control inflammatory pain
deserves to be investigated further.
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